Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to stop CMV in kidney transplants

NCT ID NCT07203664

Disease control Sponsor: Hospital Universitario La Paz Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two different drug combinations to prevent cytomegalovirus (CMV) infection in kidney transplant patients who are at high risk. Thirty adults who are CMV-positive before transplant will receive either tacrolimus plus mTOR inhibitors with early antiviral treatment, or tacrolimus plus mycophenolic acid with standard preventive antivirals. The goal is to see which strategy better prevents CMV disease and monitors immune response.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tacrolimus, mTOR inhibitors, mycophenolic acid, valganciclovir
What this could lead to
If successful, this could point toward a more effective CMV prevention strategy for kidney transplant patients, reducing infection and complications.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to all patients. The study is not yet recruiting, and the interventions carry risks like infection or organ rejection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or more. * Positive pre-transplant Ig G CMV serology. * Receive immunosuppressive induction treatment with thymoglobulin (between 1 and 5 doses). * Agree to participate in the study by signing the informed consent form. Exclusion Criteria: * Patients with negative pre-transplant Ig G CMV serology. * HIV-infected patients. * Patients receiving induction therapy with basiliximab. * Patients who cannot comply with the follow-up protocol. * Patients who cannot receive iMTOR as initial maintenance immunosuppressive therapy, such as patients with chronic kidney disease secondary to hepatorenal polycystic kidney disease and patients who are expected to undergo complex vascular surgery. * Patients who for any reason should not be included in the study according to the evaluation of the research team.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage renal disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

end stage renal failure cytomegalovirus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Evaluate the effectiveness of CMV prevention strategies in kidney transplant recipients

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Universitario La Paz, Pº de la Castellana, 261 (Servicio de Nefrologia)

    Madrid, Madrid, 28046, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.